Mixtures of ibandronate monosodium salt with eleven gluco- and/or galacto-pyranoside derivatives as counterions were designed to prepare co-crystals with improved intestinal absorption. In general, gastrointestinal absorption of bisphosphonates after oral administration is approximately 1%. Co-crystals were generated by means of thermodynamically and/or kinetically controlled crystallization processes. Seventy-seven prepared samples were analyzed by means of FT-NIR, FT-Raman spectrometry and solid state NMR spectroscopy. New entities of ibandronate monosodium salt with phenyl-β-D-galactopyranoside were found and characterized. The absorption of these potential new co-crystals was investigated by means of PAMPA experiments. In the present study the relationships between the chemical structures of the studied compounds required for co-crystal generation are discussed.

Zentiva k s U Kabelovny 130 102 37 Prague 10 Czech Republic

Zobrazit více v PubMed

Ebetino F.H., Francis M.D., Rogers M.J., Russell R.G.G. Mechanisms of action of etidronate and other bisphosphonates. Rev. Contemp. Pharmacother. 1998;9:233–243.

Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., Rodan G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 1991;88:2095–2105. doi: 10.1172/JCI115539. PubMed DOI PMC

Carano A., Teitelbaum S.L., Konsek J.D., Schlesinger P.H., Blair H.C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J. Clin. Invest. 1990;85:456–461. doi: 10.1172/JCI114459. PubMed DOI PMC

Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., Boyce B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 1995;10:1478–1487. doi: 10.1002/jbmr.5650101008. PubMed DOI

Selander K.S., Monkkonen J., Karhukorpi E.K., Harkonen P., Hannuniemi R., Vaananen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 1996;50:1127–1138. PubMed

Ito M., Amizuka N., Nakajima T., Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone. 1999;25:447–452. doi: 10.1016/S8756-3282(99)00197-0. PubMed DOI

Reszka A.A., Halasy-Nagy J.M., Masarachia P.J., Rodan G.A. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J. Biol. Chem. 1999;274:34967–34973. doi: 10.1074/jbc.274.49.34967. PubMed DOI

Rogers M.J., Xiong X., Brown R.J., Watts D.J., Russell R.G., Bayless A.V., Ebetino F.H. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol. Pharmacol. 1995;47:398–402. PubMed

Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., Frith J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961–2978. doi: 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L. PubMed DOI

van Beek E.R., Lowik C.W., Ebetino F.H., Papapoulos S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone. 1998;23:437–442. doi: 10.1016/S8756-3282(98)00120-3. PubMed DOI

MedicineNet. [(accessed on 16 November 2010)]; http://www.medicinenet.com/ibandronate/article.htm/

Ezra A., Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Advan. Drug Delivery Rev. 2000;42:175–195. doi: 10.1016/S0169-409X(00)00061-2. PubMed DOI

Kerns E.H., Li D. Drug-like Properties: Concept, Structure Design and Methods. Elsevier; San Diego, CA, USA: 2008.

Pharmaterials Ltd. [(accessed on 16 November 2010)]; http://www.pharmaterials.co.uk/co-crystals.html/

Tiekink E.R.T., Vittal J., editors. Frontiers in Crystal Engineering. Wiley-VCH; Wienheim, Germany: 2005.

Braga D., Grepioni F., editors. Making Crystals by Design: Methods, Techniques and Applications. Wiley-VCH; Wienheim, Germany: 2006.

Luypaert J., Massart D.L., Vander-Heyden Y. Near-infrared spectroscopy applications in pharmaceutical analysis. Talanta. 2007;72:865–883. doi: 10.1016/j.talanta.2006.12.023. PubMed DOI

Jampilek J., Oktabec Z., Pekarek T., Havlicek J., Dohnal J., Kral V. Characterization of polymorphs and API-excipient co-crystals using vibration spectroscopy and solid-state NMR; Proceedings of the 11th International Workshop on Physical Characterization of Pharmaceutical Solids (IWPCPS® 11); Stamford, Connecticut, USA. 14-19 June 2009.

Jampilek J., Oktabec Z., Rezacova A., Placek L., Kos J., Havelkova L., Dohnal J., Kral V. Preparation and properties of new co-crystals of ibandronate; Proceedings of the 13th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-13); 1-30 November 2009; http://www.sciforum.net/presentation/201.

Jampilek J., Kos J., Oktabec Z., Mandelova Z., Pekarek T., Tkadlecova M., Havlicek J., Dohnal J., Kral V. Co-crystal screening study of risedronate and unsubstituted hexoses; Proceedings of the 14th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-14); 1-30 November 2010; http://www.sciforum.net/presentation/421.

Eiermann U., Junghans B., Knipp B., Sattelkau T., Hoffmann-La Roche, Inc. Ibandronate polymorph B. WO/2006/081962. 2006 Aug 10;

Eiermann U., Junghans B., Knipp B., Sattelkau T., Hoffmann-La Roche, Inc. Ibandronate polymorph A. WO/2006/081963. 2006 Oct 8;

Lifshitz-Liron R., Bayer T., Aronhime J., TEVA Pharmaceutical Solid and crystalline ibandronate sodium and processes for preparation thereof. WO/2006/024024. 2006 Feb 3;

Muddasani P.R., Vattikuti U., Nannapaneni V.C., NATCO Pharma, Ltd. Novel polymorphic forms of ibandronate. WO/2007/074475. 2007 May 7;

Devarakonda S.N., Thaimattam R., Raghupati B., Asnani M., Vasamsetti S.K., Rangineni S., Muppidi V.K., Dr. Reddy's Laboratories, Ltd. Ibandronate sodium polymorphs. Application US2010/0125149 A1. U.S. Patent. 2010 May 20;

Preparation of risedronate nanoparticles by solvent evaporation technique

Crystallization products of risedronate with carbohydrates and their substituted derivatives